CLEARSIDE BIOMEDICAL INC (CLSD) Fundamental Analysis & Valuation

NASDAQ:CLSD • US1850632035

0.41 USD
-0.15 (-26.96%)
At close: Nov 28, 2025
0.3516 USD
-0.06 (-14.24%)
After Hours: 11/28/2025, 8:20:31 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CLSD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CLSD. CLSD was compared to 193 industry peers in the Pharmaceuticals industry. CLSD may be in some trouble as it scores bad on both profitability and health. CLSD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. CLSD Profitability Analysis

1.1 Basic Checks

  • In the past year CLSD has reported negative net income.
  • In the past year CLSD has reported a negative cash flow from operations.
  • In the past 5 years CLSD reported 4 times negative net income.
  • CLSD had a negative operating cash flow in each of the past 5 years.
CLSD Yearly Net Income VS EBIT VS OCF VS FCFCLSD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

  • With a Return On Assets value of -180.75%, CLSD is not doing good in the industry: 89.58% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -180.75%
ROE N/A
ROIC N/A
ROA(3y)-98.81%
ROA(5y)-77.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLSD Yearly ROA, ROE, ROICCLSD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200 -300

1.3 Margins

  • CLSD has a Gross Margin of 90.47%. This is amongst the best in the industry. CLSD outperforms 92.19% of its industry peers.
  • CLSD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLSD Yearly Profit, Operating, Gross MarginsCLSD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K -250K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CLSD Health Analysis

2.1 Basic Checks

  • CLSD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CLSD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CLSD has more shares outstanding
  • CLSD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLSD Yearly Shares OutstandingCLSD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
CLSD Yearly Total Debt VS Total AssetsCLSD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • CLSD has an Altman-Z score of -37.33. This is a bad value and indicates that CLSD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -37.33, CLSD is doing worse than 90.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -37.33
ROIC/WACCN/A
WACC9.14%
CLSD Yearly LT Debt VS Equity VS FCFCLSD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

  • CLSD has a Current Ratio of 3.87. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.87, CLSD perfoms like the industry average, outperforming 58.33% of the companies in the same industry.
  • CLSD has a Quick Ratio of 3.87. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.
  • CLSD has a Quick ratio (3.87) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.87
Quick Ratio 3.87
CLSD Yearly Current Assets VS Current LiabilitesCLSD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CLSD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 19.53% over the past year.
  • The Revenue for CLSD has decreased by -79.77% in the past year. This is quite bad
  • CLSD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.17% yearly.
EPS 1Y (TTM)19.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24%
Revenue 1Y (TTM)-79.77%
Revenue growth 3Y-61.68%
Revenue growth 5Y-5.17%
Sales Q2Q%-80.64%

3.2 Future

  • CLSD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.61% yearly.
  • The Revenue is expected to grow by 132.04% on average over the next years. This is a very strong growth
EPS Next Y56.93%
EPS Next 2Y27.07%
EPS Next 3Y17.32%
EPS Next 5Y31.61%
Revenue Next Year102.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y132.04%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLSD Yearly Revenue VS EstimatesCLSD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
CLSD Yearly EPS VS EstimatesCLSD Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. CLSD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CLSD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLSD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLSD Price Earnings VS Forward Price EarningsCLSD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLSD Per share dataCLSD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

  • CLSD's earnings are expected to grow with 17.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.07%
EPS Next 3Y17.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CLSD Dividend Analysis

5.1 Amount

  • CLSD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CLSD Fundamentals: All Metrics, Ratios and Statistics

CLEARSIDE BIOMEDICAL INC

NASDAQ:CLSD (11/28/2025, 8:20:31 PM)

After market: 0.3516 -0.06 (-14.24%)

0.41

-0.15 (-26.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)03-25
Inst Owners13.68%
Inst Owner Change-74.45%
Ins Owners7.32%
Ins Owner Change0%
Market Cap2.14M
Revenue(TTM)1.66M
Net Income(TTM)-27.71M
Analysts50.91
Price Target61.2 (14826.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.21%
Min EPS beat(2)0.67%
Max EPS beat(2)41.76%
EPS beat(4)3
Avg EPS beat(4)15.66%
Min EPS beat(4)-0.93%
Max EPS beat(4)41.76%
EPS beat(8)6
Avg EPS beat(8)12.33%
EPS beat(12)6
Avg EPS beat(12)-17.47%
EPS beat(16)9
Avg EPS beat(16)-10.12%
Revenue beat(2)2
Avg Revenue beat(2)713.73%
Min Revenue beat(2)183.74%
Max Revenue beat(2)1243.71%
Revenue beat(4)4
Avg Revenue beat(4)556.39%
Min Revenue beat(4)69.81%
Max Revenue beat(4)1243.71%
Revenue beat(8)6
Avg Revenue beat(8)324.98%
Revenue beat(12)8
Avg Revenue beat(12)278.94%
Revenue beat(16)10
Avg Revenue beat(16)207.31%
PT rev (1m)-4.76%
PT rev (3m)1328.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1400%
EPS NY rev (1m)11.63%
EPS NY rev (3m)-1225.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-2.58%
Revenue NY rev (3m)-2.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.19
EYN/A
EPS(NY)-2.6
Fwd EYN/A
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0.8
BVpS-9.32
TBVpS-9.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -180.75%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.47%
FCFM N/A
ROA(3y)-98.81%
ROA(5y)-77.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.66%
Cap/Sales 12.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.87
Quick Ratio 3.87
Altman-Z -37.33
F-Score3
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)1083.74%
Cap/Depr(5y)656.91%
Cap/Sales(3y)33.04%
Cap/Sales(5y)19.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24%
EPS Next Y56.93%
EPS Next 2Y27.07%
EPS Next 3Y17.32%
EPS Next 5Y31.61%
Revenue 1Y (TTM)-79.77%
Revenue growth 3Y-61.68%
Revenue growth 5Y-5.17%
Sales Q2Q%-80.64%
Revenue Next Year102.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y132.04%
EBIT growth 1Y15.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.3%
EBIT Next 3Y17.64%
EBIT Next 5YN/A
FCF growth 1Y13.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.81%
OCF growth 3YN/A
OCF growth 5YN/A

CLEARSIDE BIOMEDICAL INC / CLSD FAQ

What is the fundamental rating for CLSD stock?

ChartMill assigns a fundamental rating of 2 / 10 to CLSD.


Can you provide the valuation status for CLEARSIDE BIOMEDICAL INC?

ChartMill assigns a valuation rating of 0 / 10 to CLEARSIDE BIOMEDICAL INC (CLSD). This can be considered as Overvalued.


What is the profitability of CLSD stock?

CLEARSIDE BIOMEDICAL INC (CLSD) has a profitability rating of 1 / 10.


How financially healthy is CLEARSIDE BIOMEDICAL INC?

The financial health rating of CLEARSIDE BIOMEDICAL INC (CLSD) is 3 / 10.